Phase II Study of TAS-106 in Patients With Recurrent or Metastatic Head and Neck Cancer Refractory to Platinum Based Chemotherapy.

Trial Profile

Phase II Study of TAS-106 in Patients With Recurrent or Metastatic Head and Neck Cancer Refractory to Platinum Based Chemotherapy.

Discontinued
Phase of Trial: Phase II

Latest Information Update: 04 Sep 2012

At a glance

  • Drugs TAS 106 (Primary)
  • Indications Head and neck cancer
  • Focus Therapeutic Use
  • Most Recent Events

    • 23 Mar 2012 Actual patient number (27) added as reported by ClinicalTrials.gov.
    • 23 Mar 2012 Planned end date changed from 1 Dec 2011 to 1 Feb 2012 as reported by ClinicalTrials.gov.
    • 23 Mar 2012 Status changed from active, no longer recruiting to discontinued as reported by ClinicalTrials.gov.
Restricted Access

Oops, it looks like you don’t have a valid subscription to this content. To gain full access to the content and functionality of the AdisInsight database try one of the following.

  • with a username/password associated to an account with a valid subscription
  • Contact your organization’s admin about adding this content to your AdisInsight subscription
  • Request a trial

If you are a subscriber to this content then contact us at AsktheExpert.AdisInsight@springer.com so we can help.

Back to top